🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Relapsed/Refractory Peripheral T-cell Lymphoma

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas NCT06176690Phase 12 sites📍 Houston📍 Houston Baylor College of Medicine · Tests: C7R.CD30.CAR-EBVST cells Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL NCT06874946Phase 1, Phase 21 site📍 Beijing Peking University People's Hospital · Tests: CD5-targeted CAR-T cells GVM±R in Patients With Relapsed or Refractory Aggressive NHL. NCT06244368Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: GVM±R regimen A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL NCT06966154Phase 1, Phase 21 site📍 Shanghai Fudan University · Tests: tislezumab, golidocitinib, Selinexor A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL NCT06855823Phase 1, Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Golicitinib combined with Pomadomide Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma NCT06151106Phase 21 site📍 Xiamen The First Affiliated Hospital of Xiamen University · Tests: Chidamide combined with Duvillisib CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma NCT04083495Phase 22 sites📍 Chapel Hill📍 Winston-Salem UNC Lineberger Comprehensive Cancer Center · Tests: ATLCAR.CD30 T cells, Bendamustine, Fludarabine, Cyclophosphamide Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) NCT06810778Phase 1, Phase 21 site📍 Los Angeles Jonsson Comprehensive Cancer Center · Tests: Duvelisib, Venetoclax Evaluate the Safety and Clinical Activity of HH2853 NCT04390737Phase 1, Phase 225 sites📍 Phoenix📍 Jacksonville📍 Rochester Haihe Biopharma Co., Ltd. · Tests: HH2853 Tablets JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas NCT06716658Phase 22 sites📍 Tianjin📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: JAK1 Inhibitor A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) NCT07234162Phase 351 sites📍 Hefei📍 Hefei📍 Beijing Dizal Pharmaceuticals · Tests: Golidocitinib, Chidamide, Gemcitabine Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL) NCT05833724Phase 26 sites📍 Kaohsiung City📍 Kaohsiung City📍 New Taipei City Great Novel Therapeutics Biotech & Medicals Corporation · Tests: Chidamide Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma NCT06909877Phase 1, Phase 21 site📍 Chengdu Haihe Biopharma Co., Ltd. · Tests: HH2853 Tablets Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma NCT07388563Phase 11 site📍 Bethesda National Cancer Institute (NCI) · Tests: azacitidine, abatacept Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma NCT06519526Phase 21 site📍 Shanghai Fudan University · Tests: SHR-0302, SHR-2554 Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma NCT06160843Phase 21 site📍 Singapore National Cancer Centre, Singapore · Tests: Pembrolizumab IV infusion Q3W, with daily oral Olaparib. An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma. NCT07598578EARLY Phase 11 site📍 Suzhou Second Affiliated Hospital of Soochow University · Tests: Azacitidine (AZA) Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma NCT07502768Phase 1, Phase 21 site📍 Shanghai Rong Tao · Tests: Tislelizumab, Zeprumetostat Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma NCT04512534Phase 21 site📍 Shanghai Fudan University · Tests: PD-1 antibody+ HDAC inhibitor Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies NCT07523555Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual… MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing NCT05794880NA1 site📍 Milwaukee Medical College of Wisconsin · Tests: Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi) Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma NCT07164560Phase 11 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: Anti-TRBC1 CAR-T cells CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas NCT07022964Phase 1, Phase 23 sites📍 Beijing📍 Shanghai📍 Shanghai Beijing GoBroad Hospital · Tests: CD5 CAR-T cells infusion Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas NCT05956041Phase 21 site📍 Ann Arbor University of Michigan Rogel Cancer Center · Tests: Pembrolizumab, Mogamulizumab Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma NCT05182957Phase 21 site📍 Suzhou The First Affiliated Hospital of Soochow University · Tests: Anti-PD-1 monoclonal antibody, Lenalidomide, Azacitidine Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma NCT06561048Phase 337 sites📍 Duarte📍 Irvine📍 San Francisco Corvus Pharmaceuticals, Inc. · Tests: Soquelitinib, Belinostat, Pralatrexate Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma NCT04234048Phase 110 sites📍 Scottsdale📍 Duarte📍 Los Angeles SciTech Development, Inc. · Tests: Fenretinide Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells NCT06420076Phase 1, Phase 21 site📍 Beijing Essen Biotech · Tests: CD5/CD7 CAR-T CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia NCT06696846Phase 11 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: CD70 CAR-NK MB-105 in Patients With CD5 Positive T-cell Lymphoma NCT06534060Phase 212 sites📍 San Diego📍 Denver📍 Tampa March Biosciences Inc · Tests: Genetic: MB-105
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy